首页 > 市场调查报告书 > 製药

眼科药物

市场调查报告书

商品编码

1544588

视网膜疾病治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Retinal Disorder Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月03日 | 出版商:

Global Market Insights Inc. | 英文 175 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在视网膜疾病盛行率不断上升和治疗技术进步的推动下，2024年至2032年全球视网膜疾病治疗市场的复合年增长率预计将达到9.6%。由于人口老化和糖尿病等慢性病发病率的上升，黄斑部病变和糖尿病视网膜病变等视网膜疾病变得越来越常见。此外，研究和开发方面不断增加的资金和努力也支持了市场。

例如，2024 年 7 月，抗盲基金会为视网膜疾病研究提供了一项为期三年、价值 150 万美元的新拨款。凯斯西储大学医学院眼科和视觉科学副教授松山茂美 (Shigemi Matsuyama) 被指派研究一种潜在的突破性口服药物。

对有效和创新治疗方案的需求正在推动市场成长。此外，药物传递系统和治疗创新的进步正在增强视网膜疾病治疗的功效，支持市场扩张。

整个视网膜疾病治疗行业根据类型、剂型、配销通路和地区进行分类。

黄斑部病变，特别是老年黄斑部病变（AMD），预计将成为视网膜疾病治疗市场的主要成长动力。 AMD 是老年人视力丧失的主要原因，推动了对有效治疗的巨大需求。黄斑部病变治疗市场包括抗 VEGF 疗法和新兴基因疗法。抗 VEGF 治疗目前使用最广泛，并已证明在减缓疾病进展和提高视力方面具有显着效果。新疗法的不断开发和治疗方案的改进将促进该领域的市场成长。

以玻璃体内注射、眼药水和植入物等剂型分类的眼部解决方案领域将大幅成长。玻璃体内注射由于直接将药物输送到玻璃体中而受到重视，确保了视网膜疾病的更高的生物利用度和疗效。眼药水和植入物在治疗领域也发挥着至关重要的作用，为患者提供友善的选择和持续的药物释放。药物传递技术的发展和创新剂型的引入正在推动眼部解决方案在视网膜疾病治疗市场的采用。

2024年至2032年，欧洲视网膜疾病治疗市场将显着成长。在有利的监管框架和促进医疗创新的政府措施的支持下，欧洲国家处于采用先进治疗方案的前沿。领先的製药和生物技术公司的存在进一步增强了市场，持续的研究和开发工作推动了针对视网膜疾病的新的和改进的疗法的推出。

产业生态系统分析
产业影响力
- 成长动力
  - 糖尿病盛行率增加
  - 老年人口不断增加
  - 技术进步
  - 提高认识和筛检计划
- 产业陷阱与挑战
  - 治疗费用高
  - 副作用和安全问题
成长潜力分析
监管环境
技术景观
- 核心技术
- 邻近技术
2023 年定价分析
- 按地区
- 按关键人物
未来市场趋势
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

主要趋势
糖尿病视网膜病变
黄斑部病变
- 干性黄斑部病变
- 湿性黄斑部病变
糖尿病黄斑水肿
视网膜静脉阻塞
其他类型

第 6 章：市场估计与预测：按剂型，2021 - 2032

主要趋势
胶囊和片剂
眼药水
眼睛解决方案
凝胶
药膏

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

主要趋势
医院药房
零售药局
网路药局

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

AbbVie Inc.
Alimera Sciences, Inc.
Alcon, Inc.
Bayer AG
Biogen Inc.
Bausch Health Companies
F. Hoffmann-La Roche Ltd.
Graybug Vision, Inc.
Merck and Co., Inc.
Novartis AG
Ophthotech Corporation
Pfizer, Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceuticals Co. Ltd.
Takeda Pharmaceutical Company Limited

简介目录

Product Code: 10121

Global Retinal Disorder Treatment Market is poised to attain a 9.6% CAGR from 2024 to 2032, driven by the increasing prevalence of retinal disorders and advancements in treatment technologies. Retinal disorders, such as macular degeneration and diabetic retinopathy, are becoming more common due to an aging population and rising rates of chronic conditions like diabetes. Additionally, the increasing funding and efforts in research and development support the market.

For instance, in July 2024, a new three-year, $1.5 million grant from the Foundation Fighting Blindness was granted for retinal disorder research. Shigemi Matsuyama, an associate professor of ophthalmology and visual sciences at Case Western Reserve University School of Medicine, was assigned to investigate a potentially groundbreaking oral drug.

The demand for effective and innovative treatment options is fueling market growth. Additionally, advancements in drug delivery systems and therapeutic innovations are enhancing the efficacy of retinal disorder treatments, supporting market expansion.

The overall Retinal Disorder Treatment Industry is classified based on the type, dosage form, distribution channel, and region.

Macular degeneration, particularly age-related macular degeneration (AMD), is anticipated to be a major growth driver within the Retinal Disorder Treatment Market. AMD is a leading cause of vision loss among the elderly, driving significant demand for effective treatments. The market for macular degeneration treatments includes both anti-VEGF therapies and emerging gene therapies. Anti-VEGF treatments are currently the most widely used and have demonstrated substantial effectiveness in slowing disease progression and improving visual acuity. The continuous development of novel therapies and improved treatment protocols will boost market growth in this segment.

The eye solutions segment, categorized by dosage forms such as intravitreal injections, eye drops, and implants, will showcase substantial growth. Intravitreal injections are gaining prominence due to their direct delivery of drugs into the vitreous body, ensuring higher bioavailability and efficacy for retinal disorders. Eye drops and implants also play a crucial role in the treatment landscape, offering patient-friendly options and sustained drug release. The evolution of drug delivery technologies and the introduction of innovative dosage forms are driving the adoption of eye solutions in the retinal disorder treatment market.

Europe will experience significant growth in the Retinal Disorder Treatment Market from 2024 to 2032. The region benefits from a robust healthcare infrastructure, high investment in medical research, and a rising prevalence of retinal disorders. European countries are at the forefront of adopting advanced treatment options, supported by favorable regulatory frameworks and government initiatives promoting healthcare innovation. The presence of leading pharmaceutical and biotechnology companies further strengthens the market, with ongoing research and development efforts driving the introduction of new and improved therapies for retinal disorders.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of diabetes
  - 3.2.1.2 Rising geriatric population
  - 3.2.1.3 Technological advancements
  - 3.2.1.4 Rising awareness and screening programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High treatment cost
  - 3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Diabetic retinopathy
5.3 Macular degeneration
- 5.3.1 Dry macular degeneration
- 5.3.2 Wet macular degeneration
5.4 Diabetic macular edema
5.5 Retinal vein occlusion
5.6 Other types

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Capsules and tablets
6.3 Eye drops
6.4 Eye solutions
6.5 Gels
6.6 Ointments

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa